Prof Lawton will take over from the current ABPI President, Dr John Patterson, of AstraZeneca, in April next year. He will serve for a two-year term.
"This is a very exciting yet challenging time for the pharmaceutical industry," said Prof Lawton. "The UK Government has recognised, through various initiatives to improve the health of the nation, that modern medicines have a key role to play in providing cost-effective healthcare.
"However, global competition remains fierce, and it is vital that an industry making such a major contribution in Britain can continue to compete in an environment that encourages its ability to invest in research and development.
"I am very much looking forward to playing my part in ensuring that the pharmaceutical industry continues to be able provide top-quality jobs, a major contribution to the British economy and a healthy pipeline of modern medicines to improve patient care."
Prof Lawton gained his doctorate in psychology at the University of London, and is an honorary professor at the School of Health Science, University of Wales. He has worked for the pharmaceutical industry for the past 20 years, in various international divisions of MSD. He is currently Managing Director of MSD (UK) as well as Vice-President of MSD Europe.
For the ABPI, he has been on the Board of Management since 1992, playing an active role as a member of various advisory groups, committees and strategy groups. He is also a member of various groupings that represent the industry, including the Pharmaceutical Industry Competitiveness Task Force and the Ministerial Industry Strategy Group. Prof Lawton has also been Chairman of the American Pharmaceutical Group since 1999.
Note to Editors
A photograph of Prof Lawton is available electronically from the ABPI. Please contact us (details below) if you require it.
Merck Sharp & Dohme Ltd (MSD) is the UK subsidiary of Merck & Co Inc, of Whitestation, New Jersey, USA, a leading research-based pharmaceutical company that discovers, develops, manufactures and markets a wide range of innovative pharmaceutical products to improve human health.
For further information, please contact: ABPI Press Office 020 7747 1410